Gland Pharma (NSE:GLAND) Gross Margin % : 61.22% (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Gland Pharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Gland Pharma's Gross Profit for the three months ended in Dec. 2023 was ₹9,459 Mil. Gland Pharma's Revenue for the three months ended in Dec. 2023 was ₹15,452 Mil. Therefore, Gland Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was 61.22%.

Warning Sign:

Gland Pharma Ltd gross margin has been in long-term decline. The average rate of decline per year is -2.1%.

The historical rank and industry rank for Gland Pharma's Gross Margin % or its related term are showing as below:

NSE:GLAND' s Gross Margin % Range Over the Past 10 Years
Min: 51.89 Med: 56.71 Max: 60.27
Current: 60.27

During the past 6 years, the highest Gross Margin % of Gland Pharma was 60.27%. The lowest was 51.89%. And the median was 56.71%.

NSE:GLAND's Gross Margin % is ranked better than
73.35% of 987 companies
in the Drug Manufacturers industry
Industry Median: 46.24 vs NSE:GLAND: 60.27

Gland Pharma had a gross margin of 61.22% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Gland Pharma was -2.10% per year.

Gland Pharma Gross Margin % Historical Data

The historical data trend for Gland Pharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gland Pharma Gross Margin % Chart

Gland Pharma Annual Data

Trend

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Gross Margin %

Get a 7-Day Free Trial

57.00

57.15

56.42

51.89

53.08

Gland Pharma Quarterly Data
	Mar18	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial															54.48	51.50	62.53	62.02	61.22

Competitive Comparison of Gland Pharma's Gross Margin %

For the Drug Manufacturers - General subindustry, Gland Pharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gland Pharma's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Gland Pharma's Gross Margin % falls into.

Gland Pharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Gland Pharma's Gross Margin for the fiscal year that ended in Mar. 2023 is calculated as

Gross Margin % (A: Mar. 2023 )	=	Gross Profit (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	19064.3	/	35918.59
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(35918.59 - 16854.27)	/	35918.59
	=	53.08 %

Gland Pharma's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	9459.2	/	15451.55
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(15451.55 - 5992.39)	/	15451.55
	=	61.22 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Gland Pharma (NSE:GLAND) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Gland Pharma had a gross margin of 61.22% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Gland Pharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Gland Pharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Gland Pharma (NSE:GLAND) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gland Pharma Ltd (NSE:GLAND) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

543245:India

Address

Plot No. 11 and 84, TSIIC Phase: IV, Pashamylaram (V), Patancheru (M), Sangareddy District, Hyderabad, TG, IND, 502307

Website

https://www.glandpharma.com

Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, Daptomycin Injection, among others. Further, the group is involved in vast range of therapeutic categories that include Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarial, Cardiology and more - to Hormones and related Drugs, Fertility Supplements and Gnrh Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA.

Gland Pharma (NSE:GLAND) Headlines

No Headlines